Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Commercial Officer

CLO & GC

President

SVP, GC & Secretary

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-05-01	Premium	acquired	Premium	Premium	Premium	-
2024-04-16	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2024-03-18	Premium	sold	Premium	Premium	Premium	CLO & GC
2024-03-18	Premium	sold	Premium	Premium	Premium	CFO
2024-03-18	Premium	sold	Premium	Premium	Premium	President
2024-03-15	Premium	sold (taxes)	Premium	Premium	Premium	CFO
2024-03-15	Premium	sold (taxes)	Premium	Premium	Premium	CEO
2024-03-15	Premium	sold (taxes)	Premium	Premium	Premium	President
2024-03-15	Premium	sold (taxes)	Premium	Premium	Premium	CLO & GC
2024-03-06	Premium	bought	Premium	Premium	Premium	CEO
2024-02-29	Premium	acquired	Premium	Premium	Premium	President
2024-02-29	Premium	acquired	Premium	Premium	Premium	CLO & GC
2024-02-29	Premium	acquired	Premium	Premium	Premium	CFO
2024-02-29	Premium	acquired	Premium	Premium	Premium	CEO
2024-01-31	Premium	acquired	Premium	Premium	Premium	SVP, GC & Secretary
2024-01-31	Premium	acquired	Premium	Premium	Premium	CFO
2023-12-31	Premium	acquired	Premium	Premium	Premium	CFO
2023-12-31	Premium	acquired	Premium	Premium	Premium	President
2023-12-31	Premium	acquired	Premium	Premium	Premium	CEO

RVNC - Revance Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RVNC